November 7th, 2024 “EURETINA-Brief”© Issue No. 303
Dear EURETINA Members, A very warm welcome to the November 7th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue…
EURETINA’s
DIGITAL
NEWSLETTER
Featured Articles
1
November 7th, 2024
Latest News
November 7th, 2024 “EURETINA-Brief”© Issue No. 303
Dear EURETINA Members, A very warm welcome to the November 7th, 2024 edition of EURETINA’s…
A novel IRD candidate gene, UBAP1L, provides a loss-of-function causing macular, cone and cone-rod dystrophy.
Researchers at the Ophthalmic Genetics and Visual Function Branch, National Eye Institute, Bethesda, Maryland, USA…
Dose escalation study of ASTN-101 (AAV5-GUCY2D) for LCA1 patients provide improvement in FST and BCVA (Phase 1/2).
Clinical researchers at the Center for Hereditary Retinal Degenerations, Scheie Eye Institute, University of Pennsylvania,…
EyePoint Pharmaceuticals announce interim results from a Phase 2 EYP-1901 treatment (a tyrosine kinase inhibitor with a sustained delivery insert) for DME patients.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), based in Watertown, Massachusetts, have announced positive interim 16-week data…